Myriad Announces Prolaris(R) Test Biopsy Results From

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

SALT LAKE CITY and ZURICH, Switzerland, March 20, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30 th Annual Congress of the European Association of Urology.

"EMPATHY-P showed that Prolaris provides valuable clinical information that can help physicians improve healthcare and outcomes for their patients with early prostate cancer," said Colin Hayward, M.D., European medical director, Myriad. "There is no one-size-fits-all treatment approach in prostate cancer. Prolaris provides objective genetic information to help clinicians tailor treatment plans based on patients' individual risk profiles."

The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods (D'Amico/AUA risk stratification), which were then compared to the Prolaris test results.

The EMPATHY-P data showed, overall, that the Prolaris test found 42 percent of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51 percent of U.S. patients had a risk profile that differed from clinical pathology. Specifically, EMPATHY-P demonstrated that the Prolaris test score found 22 percent of the European patients had less aggressive prostate cancer and 20 percent had more aggressive prostate cancer compared to standard clinical pathology measurements.

"Prolaris has been shown in multiple clinical studies to be more effective than clinical pathology at determining the aggressiveness of prostate cancer and providing patients with an accurate risk profile based on their own genetic signature," said Hayward. "Our data showed comparable results for both European and U.S. patients. In both groups, men with a low Prolaris score are good candidates for active surveillance, while patients with a high Prolaris score may need more aggressive care."

Poster Presentation Details at EAU

Title: Poster #321 – European multi-centre study to assess the aggressiveness
  of prostate carcinoma in newly diagnosed patients using a cell-cycle gene
  expression assay. (Prolaris) in biopsy specimens (EMPATHY-P Study).
Presenter: E. Porpiglia.
Date: Poster Session 26 – Sunday, March 22, 2015, 8:45 a.m. to 10:15 a.m. 
Room: Room Paris. 

About Prolaris ®

Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy. For more information visit: www.prolaris.com .

About Myriad Genetics GmbH

Myriad Genetics GmbH is based in Zurich, Switzerland and is the international subsidiary of Myriad Genetics Inc., a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. For more information on how Myriad Genetics GmbH is making a difference, please visit the Company's European website: www.myriadgenetics.eu/ .

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions, and assess risk of disease progression and recurrence. Myriad is focused on strategic initiatives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, and expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

Myriad, the Myriad logo, BART, BRAC Analysis , Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the EMPATHY-P study data with Prolaris ® being featured at the 30 th Annual Congress of the European Association of Urology; the ability of the Prolaris test to provide valuable clinical information to help physicians improve care and health outcomes for their patients with prostate cancer; the ability of the Prolaris test to more effectively stratify patients based on their risk profile than clinical pathology; and the Company's strategic directives under the caption "About Myriad Genetics." These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing to new testing services, including unexpected costs and delays; risks related to changes in the governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact: Ron Rogers (801) 584-3065 Investor Contact: Scott Gleason (801) 584-1143

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 181

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 100

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Review Lawsuit Against Cepton, Inc. (CPTN)

Updated Category News Views 203

Class Action Against Cepton, Inc. Unveiled Recent developments have raised significant concerns for investors of Cepton, Inc. (NASDAQ: CPTN) following revelations of a class action lawsuit. Leading national plaintiffs' law firm Berger Montague has stepped in to help those impacted. The lawsuit focuses on investors who bought or sold Cepton shares during a specified...

Continue Reading
Exploring Uber Technologies: A Strategic Trade Perspective

Updated Category News Views 172

Uber Technologies Inc.'s Current Market Position Recently, ride-sharing giant Uber Technologies, Inc. (NYSE: UBER) experienced a notable increase in its market value. This uplift followed an innovative announcement regarding the capability for riders to book an Avride robotaxi, showcasing the evolution of autonomous mobility solutions. In the past five trading days, UBER...

Continue Reading
Celebrating Diversity: Winners of the Art Limitless Contest

Updated Category News Views 168

Celebrating the Art Limitless Competition Winners In the heart of artistic innovation, BE OPEN has unveiled the winners of the Art Limitless competition, an initiative celebrating inclusivity and diversity in the arts. This remarkable program strives to empower artists with disabilities, showcasing their work while inspiring broader societal awareness. What is Art...

Continue Reading
Certuity Welcomes Constantine Hatzivassiliou as New Partner

Updated Category News Views 246

Certuity Welcomes Constantine Hatzivassiliou as New Partner Certuity, a leading multi-family office dedicated to serving high-net-worth individuals and families, is thrilled to announce the promotion of Managing Director Constantine Hatzivassiliou to Partner. This significant advancement not only reflects Hatzivassiliou's commitment to the firm but also the invaluable...

Continue Reading
Sila Realty Trust, Inc.'s Key Updates on Q3 2024 Earnings

Updated Category News Views 124

Sila Realty Trust, Inc. Announces Upcoming Q3 Earnings Release Sila Realty Trust, Inc. (NYSE: SILA) recently made an announcement regarding its anticipated financial results for the third quarter of 2024. The company will release these earnings on a Tuesday morning, just before the market opens. This timely communication reflects Sila's commitment to transparency and...

Continue Reading